Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Neuromuscular blockade

Neuromuscular blockade

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Neuromuscular blockade

44 trials tracked for Neuromuscular blockade: 27 in phase 3 or 4 and 8 with published results. The most-cited published study has 261 citations.

44Trials tracked
27Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 19 Phase 3 8 Phase 2 5 Other / NA 12
  1. Phase 4 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Completed · 261 cited
  2. Phase 4 The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications Completed · 141 cited
  3. Phase 4 Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146) Completed · 29 cited
  4. Phase 4 Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) Completed · 26 cited
  5. Phase 4 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Completed · 14 cited
  6. Phase 4 Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) Completed · 12 cited
Show 38 more trials
  1. Phase 4 Sugammadex To IMprove Bowel Function Completed · 3 cited
  2. Phase 4 Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Completed
  3. Phase 4 Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery Completed
  4. Phase 4 The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy Completed
  5. Phase 4 Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery Completed
  6. Phase 4 The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery Completed
  7. Phase 4 Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency Completed
  8. Phase 4 Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients Completed
  9. Phase 4 Comparison of Time to Extubation Using Sugammadex or Neostigmine Completed
  10. Phase 4 Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block Completed
  11. Phase 4 Sugammadex as Rescue Therapy Completed
  12. Phase 4 Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure Completed
  13. Phase 4 Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade Completed
  14. Phase 3 Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) Completed
  15. Phase 3 Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773) Completed
  16. Phase 3 Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767) Completed
  17. Phase 3 Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) Completed
  18. Phase 3 Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED) Completed
  19. Phase 3 Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED) Completed
  20. Phase 3 Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED) Completed
  21. Phase 3 Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698) Completed
  22. Phase 2 Neuromuscular Blockade in Patients With Severe Renal Impairment Completed
  23. Phase 2 Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042) Completed
  24. Phase 2 Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT) Completed
  25. Phase 2 Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020). Completed
  26. Phase 2 Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children Completed
  27. N/A Understanding the Cognition and Decision Making of Community Anesthesiologists Completed
  28. N/A The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy Completed
  29. N/A Sugammadex Provide Better Surgical Condition Compared With Neostigmine in Laryngeal Microsurgery. Completed
  30. N/A Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT) Completed
  31. N/A Study on the Level of Neuromuscular Blockade Completed
  32. N/A Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals Completed
  33. N/A Effectiveness of Deep Versus Moderate Neuromuscular Blockade Completed
  34. N/A Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning Completed
  35. N/A Incidence of Incomplete Postoperative Neuromuscular Recovery From Anesthesia (P07535)(Completed) Completed
  36. N/A Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety Completed
  37. N/A Incidence of Postoperative Residual Neuromuscular Blockade in Portugal Completed
  38. N/A Evaluation of the Tof Cuff for Perioperative Neuromuscular Transmission Completed

Showing the 44 most-cited and recently-updated of 44 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Neuromuscular blockade: what the trials found

Sugammadex is associated with rapid reversal of neuromuscular blockade. Studies demonstrated significantly shorter times to reach a Train of Four (TOF) ratio of ≥0.9 compared to other interventions [3, 4, 7, 8]. Specifically, Sugammadex 2 mg/kg was shown to significantly reduce the Time to Neuromuscular Recovery (TTNMR) in moderate blocks 5 and provide rapid recovery of the T4/T1 ratio [21, 22].

Clinical safety data for Sugammadex indicates it does not significantly impact heart rate (sinus bradycardia or tachycardia) 3 or gastric emptying 7. Furthermore, Sugammadex was associated with a low incidence of bleeding events and no significant changes in aPTT or PT (INR) at 10 or 60 minutes post-administration 20.

Neostigmine and neostigmine/glycopyrrolate are established reversal agents. Neostigmine was associated with a significantly faster time to reach a TOF ratio of ≥0.9 compared to a comparator 6. Neostigmine/glycopyrrolate was associated with specific times to return of baseline muscle tone and extubation 11.

Rocuronium was evaluated in various contexts, including its impact on surgical conditions [1, 17] and intraabdominal distance 19. Succinylcholine was associated with specific surgical condition scores and postoperative pulmonary complications 15.

For the clinician treating this condition

  • Sugammadex provides rapid and consistent reversal of neuromuscular blockade, significantly reducing the time to reach a TOF ratio of ≥0.9 compared to other agents [3, 4, 7, 8].
  • Sugammadex demonstrates a favorable safety profile regarding cardiac rhythm, gastric motility, and coagulation parameters [3, 7, 20].
  • Neostigmine is an established reversal agent, though specific recovery times for muscle tone and extubation vary based on the specific combination used (e.g., with glycopyrrolate) [6, 11].

AI synthesis of 8 cited trials, updated Sep 18, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sugammadex selectively reverses rocuronium blockade within 3 minutes, review reports
Drug Pipeline Sys. Review
Sugammadex selectively reverses rocuronium blockade within 3 minutes, review reports Sugammadex quickly reverses muscle paralysis caused by rocuronium
This narrative review examines sugammadex for reversal of neuromuscular blockade, covering mechanism of action, pharmacokinetics, dosing, ad…
A new way to quickly reverse muscle paralysis during surgery can work in under three minutes, helping patients wake up faster and safer.
Frontiers Sep 17, 2026